Ilyang Pharm (007570) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.009x

Based on the latest financial reports, Ilyang Pharm (007570) has a cash flow conversion efficiency ratio of 0.009x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.26 Billion ≈ $1.53 Million USD) by net assets (₩239.41 Billion ≈ $162.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ilyang Pharm (007570) net asset quality to measure how much of total assets are equity-financed.

Ilyang Pharm - Cash Flow Conversion Efficiency Trend (2003–2024)

This chart illustrates how Ilyang Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ilyang Pharm cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Ilyang Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ilyang Pharm ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Tipco Foods Public Company Limited BK:TIPCO	-0.012x
Western Asset Investment Grade Defined Opportunity Closed Fund NYSE:IGI	N/A
Immunoprecise Antibodies Ltd NASDAQ:IPA	-0.048x
In The F KO:014990	0.009x
Semen Baturaja Persero Tbk JK:SMBR	0.008x
Bionet TWO:1784	0.013x
CGRE AG XETRA:CGX	N/A
Eastland Equity Bhd KLSE:2097	0.051x

Annual Cash Flow Conversion Efficiency for Ilyang Pharm (2003–2024)

The table below shows the annual cash flow conversion efficiency of Ilyang Pharm from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Ilyang Pharm.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩241.58 Billion ≈ $163.71 Million	₩5.61 Billion ≈ $3.81 Million	0.023x	-65.79%
2023-12-31	₩196.41 Billion ≈ $133.10 Million	₩13.34 Billion ≈ $9.04 Million	0.068x	-33.76%
2022-12-31	₩291.85 Billion ≈ $197.79 Million	₩29.94 Billion ≈ $20.29 Million	0.103x	-58.41%
2021-12-31	₩271.76 Billion ≈ $184.17 Million	₩67.02 Billion ≈ $45.42 Million	0.247x	+5.08%
2020-12-31	₩244.92 Billion ≈ $165.98 Million	₩57.48 Billion ≈ $38.96 Million	0.235x	+44.44%
2019-12-31	₩222.74 Billion ≈ $150.95 Million	₩36.19 Billion ≈ $24.53 Million	0.162x	+54.17%
2018-12-31	₩209.88 Billion ≈ $142.23 Million	₩22.12 Billion ≈ $14.99 Million	0.105x	-25.94%
2017-12-31	₩210.98 Billion ≈ $142.98 Million	₩30.03 Billion ≈ $20.35 Million	0.142x	+14.64%
2016-12-31	₩217.35 Billion ≈ $147.30 Million	₩26.98 Billion ≈ $18.29 Million	0.124x	-34.96%
2015-12-31	₩211.00 Billion ≈ $142.99 Million	₩40.27 Billion ≈ $27.29 Million	0.191x	+87.97%
2014-12-31	₩183.46 Billion ≈ $124.33 Million	₩18.63 Billion ≈ $12.62 Million	0.102x	+714.91%
2013-12-31	₩183.88 Billion ≈ $124.61 Million	₩-3.04 Billion ≈ $-2.06 Million	-0.017x	-112.63%
2003-12-31	₩77.13 Billion ≈ $52.27 Million	₩10.08 Billion ≈ $6.83 Million	0.131x	--

About Ilyang Pharm

KO:007570 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$95.48 Million

₩140.89 Billion KRW

Market Cap Rank

#19328 Global

#922 in Korea

Share Price

₩7860.00

Change (1 day)

+0.00%

52-Week Range

₩7860.00 - ₩13750.00

All Time High

₩95982.23